Trade Report: Today: Staley Capital Advisers Inc. Increases Stake in Pfizer Inc. (PFE)

Today: Staley Capital Advisers Inc. Increases Stake in Pfizer Inc. (PFE)

Staley Capital Advisers Inc. boosted its position in Pfizer Inc. (NYSE:PFE) by 0.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 949,485 shares of the biopharmaceutical company’s stock after buying an additional 8,729 shares during the period. Pfizer accounts for 3.5% of Staley Capital Advisers Inc.’s investment portfolio, making the stock its 7th largest position. Staley Capital Advisers Inc.’s holdings in Pfizer were worth $33,431,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. ST Germain D J Co. Inc. increased its position in shares of Pfizer by 3.4% in the first quarter. ST Germain D J Co. Inc. now owns 113,970 shares of the biopharmaceutical company’s stock worth $3,378,000 after buying an additional 3,778 shares during the last quarter. Lincluden Management Ltd. increased its position in shares of Pfizer by 6.6% in the first quarter. Lincluden Management Ltd. now owns 160,972 shares of the biopharmaceutical company’s stock worth $4,771,000 after buying an additional 9,925 shares during the last quarter. Bridges Investment Management Inc. increased its position in shares of Pfizer by 1.1% in the first quarter. Bridges Investment Management Inc. now owns 28,220 shares of the biopharmaceutical company’s stock worth $946,000 after buying an additional 313 shares during the last quarter. PM CAPITAL Ltd bought a new position in shares of Pfizer during the first quarter worth $39,264,000. Finally, Murphy Pohlad Asset Management LLC increased its position in shares of Pfizer by 12.8% in the first quarter. Murphy Pohlad Asset Management LLC now owns 59,141 shares of the biopharmaceutical company’s stock worth $1,752,000 after buying an additional 6,710 shares during the last quarter. 69.66% of the stock is owned by institutional investors.

Pfizer Inc. (NYSE:PFE) traded down 0.06% during midday trading on Monday, reaching $32.64. The company had a trading volume of 3,604,536 shares. The stock has a 50-day moving average price of $34.02 and a 200 day moving average price of $34.27. Pfizer Inc. has a 12-month low of $28.25 and a 12-month high of $37.39. The company has a market capitalization of $197.98 billion, a PE ratio of 28.94 and a beta of 0.86.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.02. The business earned $13.10 billion during the quarter, compared to analyst estimates of $13.01 billion. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. Pfizer’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period last year, the company earned $0.56 EPS. Equities analysts forecast that Pfizer Inc. will post $2.46 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be given a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a yield of 3.67%. The ex-dividend date is Tuesday, November 8th. Pfizer’s dividend payout ratio is currently 95.24%.

A number of brokerages recently weighed in on PFE. Vetr raised Pfizer from a “hold” rating to a “buy” rating and set a $38.08 price objective on the stock in a research note on Tuesday, August 2nd. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Pfizer in a research report on Monday, September 26th. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $54.00 price target on shares of Pfizer in a research report on Monday, June 27th. BMO Capital Markets reaffirmed a “buy” rating and issued a $40.00 price target on shares of Pfizer in a research report on Thursday, July 21st. Finally, JPMorgan Chase & Co. set a $40.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Monday, July 25th. Eleven equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $38.59.

About Pfizer

Related posts

Leave a Comment